Li Yunlong, Su Yinxia, Zhang Yangchang, Guo Zihao, Chen Zhaoyun, Li Hui, Zhang Chunyang, Chi Qiaoge, Ge Yang, Javanbakht Mohammad, Musa Salihu S, Sun Shengzhi, Tang Naijun, Wang Kai, Wang Kailu, Zhao Shi
School of Public Health, Xinjiang Medical University, Urumqi, China.
Department of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, China.
Expert Rev Clin Immunol. 2025 Jun;21(6):825-834. doi: 10.1080/1744666X.2025.2507329. Epub 2025 May 26.
The protective effects of inactivated COVID-19 vaccines against SARS-CoV-2-associated semen impairment remain underexplored. We aimed to investigate the association between BBIBP-CorV vaccination and semen quality in males recovering from SARS-CoV-2 infection.
This single-center retrospective cohort study included males recovering from SARS-CoV-2 infection at a tertiary hospital in Urumqi, China (February-May 2023). Participants were categorized into long-term (> 90 days) and short-term (≤ 90 days) effects groups based on the interval between semen collection and their most recent SARS-CoV-2 infection. The study assessed the association between different doses of BBIBP-CorV vaccination and semen quality in both groups.
A total of 1496 participants were recruited for the short-term ( = 307) and long-term effect groups ( = 1189). Participants had a median age of 32 (IQR: 30, 35) years. Compared to unvaccinated controls, 2-dose and 3-dose recipients showed reduced risk of semen quality impairment in short-term, with adjusted relative risk (RR) of 0.945 (95% CI 0.918, 0.973) and 0.965 (95% CI 0.937, 0.993), respectively. No significant results were found for long-term effect groups.
Inactivated COVID-19 vaccination may protect against semen quality impairment in males recovering from SARS-CoV-2 Omicron infection within 90 days, particularly in semen volume and sperm progressive motility.
新冠病毒灭活疫苗对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）相关精液损伤的保护作用仍未得到充分研究。我们旨在调查接种BBIBP-CorV疫苗与从SARS-CoV-2感染中康复的男性精液质量之间的关联。
这项单中心回顾性队列研究纳入了在中国乌鲁木齐一家三级医院从SARS-CoV-2感染中康复的男性（2023年2月至5月）。根据精液采集与他们最近一次SARS-CoV-2感染之间的间隔，将参与者分为长期（>90天）和短期（≤90天）效应组。该研究评估了两组中不同剂量的BBIBP-CorV疫苗接种与精液质量之间的关联。
短期效应组（n = 307）和长期效应组（n = 1189）共招募了1496名参与者。参与者的年龄中位数为32岁（四分位间距：30，35）。与未接种疫苗的对照组相比，2剂和3剂接种者在短期内精液质量受损风险降低，调整后的相对风险（RR）分别为0.945（95%置信区间0.918，0.973）和0.965（95%置信区间0.937，0.993）。长期效应组未发现显著结果。
新冠病毒灭活疫苗接种可能会保护从SARS-CoV-2奥密克戎感染中康复90天内的男性免受精液质量损伤，尤其是精液量和精子前向运动能力方面。
